BACKGROUND: Asthma has been considered an immunologic disease mediated by T(H)2 cells and adaptive immunity. However, clinical and experimental observations suggest that additional pathways might regulate asthma, particularly in its nonallergic forms, such as asthma associated with air pollution, stress, obesity, and infection. OBJECTIVES: Our goal was to understand T(H)2 cell-independent conditions that might lead to airway hyperreactivity (AHR), a cardinal feature of asthma. METHODS: We examined a murine model of experimental asthma in which AHR was induced with glycolipid antigens, which activate natural killer T (NKT) cells. RESULTS: In this model AHR developed rapidly when mice were treated with NKT cell-activating glycolipid antigens, even in the absence of conventional CD4(+) T cells. The activated NKT cells directly induced alveolar macrophages to produce IL-33, which in turn activated NKT cells, as well as natural helper cells, a newly described non-T, non-B, innate lymphoid cell type, to increase production of IL-13. Surprisingly, this glycolipid-induced AHR pathway required not only IL-13 but also IL-33 and its receptor, ST2, because it was blocked by an anti-ST2 mAb and was greatly reduced in ST2(-/-) mice. When adoptively transferred into IL-13(-/-) mice, both wild-type natural helper cells and NKT cells were sufficient for the development of glycolipid-induced AHR. CONCLUSION: Because plant pollens, house dust, and some bacteria contain glycolipids that can directly activate NKT cells, these studies suggest that AHR and asthma can fully develop or be greatly enhanced through innate immune mechanisms involving IL-33, natural helper cells, and NKT cells.
BACKGROUND: Asthma has been considered an immunologic disease mediated by T(H)2 cells and adaptive immunity. However, clinical and experimental observations suggest that additional pathways might regulate asthma, particularly in its nonallergic forms, such as asthma associated with air pollution, stress, obesity, and infection. OBJECTIVES: Our goal was to understand T(H)2 cell-independent conditions that might lead to airway hyperreactivity (AHR), a cardinal feature of asthma. METHODS: We examined a murine model of experimental asthma in which AHR was induced with glycolipid antigens, which activate natural killer T (NKT) cells. RESULTS: In this model AHR developed rapidly when mice were treated with NKT cell-activating glycolipid antigens, even in the absence of conventional CD4(+) T cells. The activated NKT cells directly induced alveolar macrophages to produce IL-33, which in turn activated NKT cells, as well as natural helper cells, a newly described non-T, non-B, innate lymphoid cell type, to increase production of IL-13. Surprisingly, this glycolipid-induced AHR pathway required not only IL-13 but also IL-33 and its receptor, ST2, because it was blocked by an anti-ST2 mAb and was greatly reduced in ST2(-/-) mice. When adoptively transferred into IL-13(-/-) mice, both wild-type natural helper cells and NKT cells were sufficient for the development of glycolipid-induced AHR. CONCLUSION: Because plant pollens, house dust, and some bacteria contain glycolipids that can directly activate NKT cells, these studies suggest that AHR and asthma can fully develop or be greatly enhanced through innate immune mechanisms involving IL-33, natural helper cells, and NKT cells.
Authors: Yuki Kinjo; Emmanuel Tupin; Douglass Wu; Masakazu Fujio; Raquel Garcia-Navarro; Mohammed Rafii-El-Idrissi Benhnia; Dirk M Zajonc; Gil Ben-Menachem; Gary D Ainge; Gavin F Painter; Archana Khurana; Kasper Hoebe; Samuel M Behar; Bruce Beutler; Ian A Wilson; Moriya Tsuji; Timothy J Sellati; Chi-Huey Wong; Mitchell Kronenberg Journal: Nat Immunol Date: 2006-08-20 Impact factor: 25.606
Authors: Steven A Saenz; Mark C Siracusa; Jacqueline G Perrigoue; Sean P Spencer; Joseph F Urban; Joel E Tocker; Alison L Budelsky; Melanie A Kleinschek; Robert A Kastelein; Taku Kambayashi; Avinash Bhandoola; David Artis Journal: Nature Date: 2010-03-03 Impact factor: 49.962
Authors: David Préfontaine; Stéphane Lajoie-Kadoch; Susan Foley; Séverine Audusseau; Ron Olivenstein; Andrew J Halayko; Catherine Lemière; James G Martin; Qutayba Hamid Journal: J Immunol Date: 2009-10-15 Impact factor: 5.422
Authors: Miriam F Moffatt; Ivo G Gut; Florence Demenais; David P Strachan; Emmanuelle Bouzigon; Simon Heath; Erika von Mutius; Martin Farrall; Mark Lathrop; William O C M Cookson Journal: N Engl J Med Date: 2010-09-23 Impact factor: 91.245
Authors: Elisabetta Agea; Anna Russano; Onelia Bistoni; Roberta Mannucci; Ildo Nicoletti; Lanfranco Corazzi; Anthony D Postle; Gennaro De Libero; Steven A Porcelli; Fabrizio Spinozzi Journal: J Exp Med Date: 2005-07-11 Impact factor: 14.307
Authors: Erin D Gordon; Joe Palandra; Agata Wesolowska-Andersen; Lando Ringel; Cydney L Rios; Marrah E Lachowicz-Scroggins; Louis Z Sharp; Jamie L Everman; Hannah J MacLeod; Jae W Lee; Robert J Mason; Michael A Matthay; Richard T Sheldon; Michael C Peters; Karl H Nocka; John V Fahy; Max A Seibold Journal: JCI Insight Date: 2016-09-08
Authors: Melissa Y Tjota; Jesse W Williams; Tiffany Lu; Bryan S Clay; Tiara Byrd; Cara L Hrusch; Donna C Decker; Claudia Alves de Araujo; Paul J Bryce; Anne I Sperling Journal: J Clin Invest Date: 2013-04-15 Impact factor: 14.808
Authors: Sanhong Yu; Krystle M Leung; Hye-Young Kim; Sarah E Umetsu; Yanping Xiao; Lee A Albacker; Hyun-Jun Lee; Dale T Umetsu; Gordon J Freeman; Rosemarie H DeKruyff Journal: J Allergy Clin Immunol Date: 2019-01-29 Impact factor: 10.793